Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. STOCKS ON THE MOVE-Lands' End, City National, Covenant

Thu, 22nd Jan 2015 14:20

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s) U.S. stock index futures pointed to modest gains at the open onThursday after the European Central Bank announced expandedmeasures to stimulate the region's economy. Dow Jones industrialaverage e-mini futures were up 0.54 percent at 17,585,S&P 500 e-mini futures were up 0.64 percent at 2,039.5and Nasdaq 100 e-mini futures were up 0.55 percent at4,205.75.

** LANDS' END INC , Wednesday close $50.71, -21.91pct premarket

The apparel retailer forecast lower revenue from merchandisesales and services in the fourth quarter. "We were disappointedby the performance of our cold weather assortment, especiallyduring the peak holiday period," Chief Executive Edgar Hubersaid. International business was affected by unfavorable changesin currency exchange rates and lower sales in Europe. Thecompany, spun off from Sears Holdings Corp last year,forecast Q4 earnings much below analysts' average estimate.

** CITY NATIONAL CORP, Wednesday close$74.57, +18.40 pct premarket

Royal Bank of Canada said it would buy theU.S. lender serving high net worth clients in a cash-and-stockdeal valued at $5.4 billion. RBC offered $47.25 in cash and0.7489 in shares for each City National share. The total offerof $93.80 per share, based on RBC's closing price of $62.16 onthe New York Stock Exchange on Wednesday, represents a premiumof nearly 26 percent to City National's last closing price.

** F5 NETWORKS INC, Wednesday close $125.95, -14.41pct premarket

The network equipment maker reported revenue that missedWall Street's estimates for the first time in eight quarters dueto "a marked decrease in the number of deals greater than $1million".

At least 8 brokerages cut price targets on the stock by asmuch as $25 to as low as $105; Median target price $133

"Comps become much more difficult in the coming quarters andthe company will have to prove that newer initiatives likesecurity can drive revenue re-acceleration and sustainabledouble-digit growth" Barclays analysts wrote in a note.

** LOGITECH INTERNATIONAL SA, Wednesday close$14.09, +8.16 pct premarket

The company increased profitability outlook for full year2015. The traders cited strong EBIT number of $76.4 mln for thethird quarter. The stock was the top riser on Stoxx 600, with a full-day's 30-day average volume alreadytraded.

** PETROBRAS , Wednesday close $7.35, +5.71 pctpremarket

** TOTAL SA , Wednesday close $51.64, +0.35 pctpremarket

** BP Plc , Wednesday close $38.82, +0.41 pctpremarket

** HALLIBURTON CO , Wednesday close $40.69, +0.27pct premarket

** SCHLUMBERGER LTD , Wednesday close $82.21, +0.57pct premarket

** SEADRILL LTD , Wednesday close $10.38, +3.37 pctpremarket

** TRANSOCEAN LTD , Wednesday close $16.06, +1.49pct premarket

** NABORS INDUSTRIES LTD , Wednesday close$10.86, +1.20 pct premarket

Brent crude rose ahead of an expected decision by EuropeanCentral Bank to start buying bonds, a move which could pushdollar to new highs and put downward pressure on commodities.Brent crude up 2 pct at $49.99 per barrel; U.S. crude up 1.5 pct at $48.49 per barrel.

** BLACKBERRY LTD, Wednesday close $9.93, +5.54 pctpremarket

Samsung Electronics Co Ltd is actively pursuinga plan to take over or buy a significant stake in the canadiancompany despite statements from both companies this weekdenying that such a plan may be in the works, Canada's FinancialPost reported. (http://bit.ly/1wpG0Ue)

** XILINX INC, Wednesday close $41.51, -7.25 pctpremarket

The programmable-chip maker's shares forecast Q3 revenue andQ4 revenue below analysts' average estimates. Results andforecast hurt by weak sales to broadcast and communicationscustomers.

At least nine brokerages cut price targets, with Robert W.Baird & Co slashing by $8.00 to $44.00

** MEDIVATION , Wednesday close $111.2, -3.39 pctpremarket

The drug developer says its prostate cancer therapy Xtandiwas not as safe as AstraZeneca Plc's treatment Casodexin a mid-stage study. 31 pct patients given Xtandi had seriousadverse reactions compared with 23.3 pct patients who were givenCasodex. Xtandi increased the time patients survived withoutprogression of the disease to 15.7 months, compared to 5.8months among Casodex patients.

** COVENANT TRANSPORTATION, Wednesday close$24.76, +9.05 pct premarket

The transportation services provider's Q4 earnings 82 centsper share came above the average analyst estimate 74 cents. Peakholiday shipping, lower fuel costs boosted profit, CEO DavidParker said.

** SANDISK CORP, Wednesday close $80.44, -6.51 pctpremarket

The memory chip maker forecast current-quarter andfull-year 2015 revenue well below Wall Street expectations,saying it would be unable to meet demand for flash memorystorage chips until mid-year due to lean inventory levels.

** KERYX BIOPHARMACEUTICALS INC, Wednesday close$12.87, -2.41 pct premarket

The drug developer's offering of 9.2 mln shares priced at$12 each, a discount of 6.8 pct to Wednesday's close. Thecompany, which had 91.9 mln shares outstanding as of Wednesday'sclose, said it would use $110 mln proceeds to fund marketing ofrecently approved chronic kidney disease treatment Auryxia.

** INTREXON CORP, Wednesday close $28.4, -1.37 pctpremarket

The synthetic biology company's offering of 3.8 millionshares priced at $27.00 each, a discount of 4.9 pct to thestock's Wednesday's closing price. Company had about 100.5 mlnshares outstanding as of Wednesday, according to Thomson Reutersdata.

** BIOMARIN PHARMACEUTICAL INC, Wednesday close$96.14, -2.86 pct premarket

The drugmaker's offering of 8.5 mln shares priced at $93.25each, a 3 pct discount to the stock's Wednesday close. THecompany had 147.4 mln shares outstanding as of Sept. 30,according to Thomson Reuters data. Says to use net proceeds tofund acquisition of Dutch drug developer Prosensa Holding NV and for general corporate purposes.

** AMERICAN EXPRESS CO, Wednesday close$87.67, -2.69 pct premarket

The world's largest credit card issuer will cut more than4,000 jobs this year, an executive said, after the credit cardcompany also reported higher quarterly expenses and provisionsfor bad loans. The planned redundancies, from a workforce ofnearly 63,000, contributed to a $313 million pre-taxrestructuring charge.

Jefferies cuts price target to $90 from $95, Barclays to $96from $100, and Bernstein to $97 from $99.

** EBAY INC, Wednesday close $53.38, +3.03 pctpremarket

The company plans to break up into three different companiesto accommodate would-be suitors, signaling a potential mergerfight after the breakup.

The company plans to spin off its payments division,PayPal, from its core marketplace division in the second half ofthe year, making two standalone publicly traded companies thatsome analysts say could be worth more than the combinedentity.

Cowen and Co raises price target to $57 from $55, RBCCapital Markets to $58 from $55 and Susquehanna Financial Groupto $59 from $52.

** VERIZON COMMUNICATIONS INC, Wednesday close$48.25, -0.41 pct premarket

THe company's quarterly revenue rose 6.8 percent due tohigher net addition of postpaid subscribers and a rise inaverage revenue per account as users added more devices toshared data plans. The company, however, reported a loss of$2.15 billion, or 54 cents per share, for the fourth quartercompared with a profit of $7.92 billion, or $1.76 per share, ayear earlier, mainly due to valuation of benefits plan andpension adjustments.

** MICROSOFT CORP, Wednesday close $45.92, +0.78pct premarket

The ageing tech pioneer surprised the tech world onWednesday with a prototype hologram visor that can bring theMinecraft video game, Skype calls and even the landscape of Marsto three-dimensional life.

** SALLIE MAE CORP, Wednesday close $9.69, -13.21pct premarket

The provider of student loans forecasted 2015 EPS of 48-50cents below analysts average estimate of 62 cents, according toThomson Reuters I/B/E/S. Net income for the fourth quarterplunged 75 pct to $14.9 million, missing analysts' averageestimate. Provision for loan losses rises 7 pct to $30 millionin Q4.

** FAMILY DOLLAR STORES INC, Wednesday close $75.55

The shareholders are expected to vote in favor of a pending$8.5 billion merger with Dollar Tree Inc despite ahigher offer from Dollar General still on the table,according to people familiar with the matter.

The vote, which is scheduled for Thursday, comes afterinfluential proxy advisory firm Institutional ShareholderServices said Dollar Tree's proposal was in the best interest ofshareholders and was more likely to close as it faces fewerantitrust hurdles than the Dollar General offer. (Compiled by Rosmi Shaji in Bengaluru; Edited by Don Sebastian)

More News
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.